Sana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Sana Biotechnology, Inc. (NASDAQ:SANA) has received a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $8.1667.

Several equities research analysts recently commented on SANA shares. Wall Street Zen cut Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. HC Wainwright dropped their price target on shares of Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Bank of America boosted their price objective on shares of Sana Biotechnology from $6.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Zacks Research upgraded shares of Sana Biotechnology from a “hold” rating to a “strong-buy” rating in a report on Friday, January 23rd. Finally, Citizens Jmp set a $8.00 target price on shares of Sana Biotechnology in a research report on Thursday, October 30th.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of SANA. Marex Group plc purchased a new stake in shares of Sana Biotechnology during the 2nd quarter valued at about $10,423,000. Balyasny Asset Management L.P. purchased a new stake in Sana Biotechnology during the fourth quarter valued at approximately $6,834,000. Vanguard Group Inc. raised its position in Sana Biotechnology by 19.9% in the third quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock worth $32,408,000 after acquiring an additional 1,517,474 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Sana Biotechnology by 180.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock worth $7,581,000 after acquiring an additional 1,375,029 shares during the last quarter. Finally, State Street Corp grew its position in shares of Sana Biotechnology by 20.6% during the 4th quarter. State Street Corp now owns 8,054,841 shares of the company’s stock valued at $32,783,000 after acquiring an additional 1,374,300 shares during the period. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Price Performance

Shares of Sana Biotechnology stock opened at $4.27 on Friday. Sana Biotechnology has a 1 year low of $1.26 and a 1 year high of $6.55. The firm has a market cap of $1.14 billion, a price-to-earnings ratio of -4.40 and a beta of 1.96. The company has a 50-day moving average of $4.33 and a 200 day moving average of $4.11.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.